S'abonner

In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione - 03/01/17

Doi : 10.1016/j.biopha.2016.11.040 
Shamim Akhtar Sufi a, b, Lakshmi Narayana Adigopula c, Safiulla Basha Syed b, d, Victor Mukherjee a, b, Mohane S. Coumar b, d, H. Surya Prakash Rao b, c, , Rukkumani Rajagopalan a, b, e,
a Department of Biochemistry and Molecular Biology, School of Life Sciences, Pondicherry University, Puducherry, 605014, India 
b DBT-Interdisciplinary Program in Life Sciences, School of Life Sciences, Pondicherry University, India 
c Department of Chemistry, School of Physical, Chemical and Applied Sciences, Pondicherry University, Puducherry, 605014, India 
d Centre for Bioinformatics, School of Life Sciences, Pondicherry University, India 
e Department of Biotechnology, University of Madras, Guindy Campus, Chennai, 600 025, India 

Corresponding author at: Department of Biotechnology, University of Madras, Guindy Campus, Chennai 600 025, India.Department of BiotechnologyUniversity of MadrasGuindy CampusChennai600 025India⁎⁎Corresponding author at: Department of Chemistry, School of Physical, Chemical and Applied Sciences, Pondicherry University, Puducherry, 605014, India.Department of ChemistrySchool of PhysicalChemical and Applied SciencesPondicherry UniversityPuducherry605014India

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages 10
Iconographies 8
Vidéos 0
Autres 0

Abstract

Purpose

Previously we showed that BDMC, an analogue of curcumin suppresses growth of human breast and laryngeal cancer cell line by causing apoptosis. Here, we demonstrate the enhanced anti-cancer activity of a heterocyclic ring (indole) incorporated curcumin analogue ((1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-Dione), ICA in short, in comparison to curcumin.

Method

ICA was synthesized by a one pot condensation reaction. Anti-cancer potential of ICA was assessed in three human cancer cell lines of different origin (Lung adenocarcinoma (A549), leukemia (K562) and colon cancer (SW480)) by MTT assay. Mode of cell death was determined by acridine orange-ethidium bromide (Ao-Eb) staining. Putative cellular targets of ICA were investigated by molecular docking studies. Cell cycle analysis following curcumin or ICA treatment in SW480 cell line was carried out by flow cytometry. Expression levels of Cyclin D1 and apoptotic markers, such as Caspase 3, 8 and 9 were studied by western blot analysis in SW480 cell line treated with or without ICA and curcumin.

Results

The yield of ICA synthesis was found to be 69% with a purity of 98%. ICA demonstrated promising anti-cancer activity compared to curcumin alone, as discerned by MTT assay. ICA was non-toxic to the cell line of normal origin. We further observed that ICA is ∼2 fold more potent than curcumin in inhibiting the growth of SW480 cells. Ao-Eb staining revealed that ICA could induce apoptosis in all the cell lines tested. Molecular docking studies suggest that ICA may possibly exhibit its anticancer effect by inhibiting EGFR in A549, Bcr-Abl in K562 and GSK-3β kinase in SW480 cell line. Moreover, ICA showed strong binding avidity for Bcl-2 protein in silico, which could result in induction of apoptosis. Cell cycle analysis revealed that both curcumin and ICA induced concomitant cell cycle arrest at G0/G1 and G2/M phase. Western blot shows that ICA could effectively down regulate the expression of cell cycle protein cyclin D1, while promoting the activation of Caspase 3, 8 and 9 when compared to curcumin in human colon cancer cell line SW480.

Conclusion

The result of this study indicates that ICA could hold promise to be a potential anti-cancer agent. Since ICA has shown encouraging results in terms of its anti-cancer activity compared to curcumin, further research is necessary to fully delineate the underlying molecular mechanism of its anticancer potential.

Le texte complet de cet article est disponible en PDF.

Abbreviations : AO-EB, ICA, DMSO, THQ

Keywords : Cancer, Curcumin analogue, Indole, Synthesis, Docking, Anticancer, Apoptosis


Plan


© 2016  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 85

P. 389-398 - janvier 2017 Retour au numéro
Article précédent Article précédent
  • Investigation for role of tissue factor and blood coagulation system in severe acute pancreatitis and associated liver injury
  • Zhi-Bing Ou, Chun-Mu Miao, Ming-Xin Ye, Ding-Pei Xing, Kun He, Pei-Zhi Li, Rong-Tao Zhu, Jian-Ping Gong
| Article suivant Article suivant
  • Estrogen and thyroid cancer is a stem affair: A preliminary study
  • Mariangela Zane, Carmelo Parello, Gianmaria Pennelli, Danyelle M. Townsend, Stefano Merigliano, Marco Boscaro, Antonio Toniato, Giovannella Baggio, Maria Rosa Pelizzo, Domenico Rubello, Isabella Merante Boschin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.